MSFT 415.85 -0.4643% AAPL 228.66 0.1665% NVDA 145.315 -1.153% GOOGL 175.65 -1.3867% GOOG 177.07 -1.3977% AMZN 202.88 -0.8455% META 564.135 0.5427% AVGO 162.61 -1.6571% TSLA 342.2799 -1.0752% TSM 186.825 -1.5% LLY 754.385 3.3786% V 307.39 -1.4302% JPM 240.935 -0.8865% UNH 601.41 4.2305% NVO 105.52 2.8159% WMT 87.12 0.6005% LVMUY 121.8 -0.5471% XOM 119.97 1.1296% LVMHF 607.0 -0.9465% MA 512.64 -1.3129%
Last update at 2024-11-20T20:38:00Z
Do Options Traders Know Something About BioMarin (BMRN) Stock We Don't?
Fri 04 Oct 24, 02:04 PM3 Reasons Why Growth Investors Shouldn't Overlook BioMarin (BMRN)
Tue 01 Oct 24, 04:45 PMBMRN or MYGN: Which Is the Better Value Stock Right Now?
Tue 01 Oct 24, 03:40 PMDown -22.94% in 4 Weeks, Here's Why You Should You Buy the Dip in BioMarin (BMRN)
Tue 01 Oct 24, 01:35 PMAndreas Halvorsen's Strategic Acquisition in BioMarin Pharmaceutical Inc
Mon 30 Sep 24, 11:03 PMHigh Growth Tech Stocks To Watch For Future Potential
Mon 30 Sep 24, 10:02 AMBioMarin (BMRN): Strong Results and ROCTAVIAN Progress Make It a Mid-Cap Growth Gem
Sat 21 Sep 24, 01:55 PMAscendis Soars on Encouraging Data From Dwarfism Drug Study
Tue 17 Sep 24, 06:12 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 149.58M | -75.35000M | -42.32200M | -94.81100M | -142.70500M |
| Minority interest | - | - | - | - | - |
| Net income | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Selling general administrative | 403.71M | 354.30M | 334.30M | 680.92M | 604.35M |
| Selling and marketing expenses | 450.30M | 405.10M | 403.40M | - | - |
| Gross profit | 1612.37M | 1375.76M | 1336.18M | 1344.58M | 1175.95M |
| Reconciled depreciation | 101.97M | 108.04M | 105.17M | 105.30M | 95.67M |
| Ebit | 57.55M | -60.01300M | -96.26000M | -125.45700M | -149.04100M |
| Ebitda | 159.51M | 48.03M | -5.85000M | -22.24300M | -100.25000M |
| Depreciation and amortization | 101.97M | 108.04M | 90.41M | 103.21M | 48.79M |
| Non operating income net other | - | 10.48M | 16.60M | 22.16M | 22.28M |
| Operating income | 57.55M | -60.01300M | -96.26000M | -125.45700M | -123.52400M |
| Other operating expenses | 2054.48M | 1928.62M | 1956.71M | 1829.51M | 1664.74M |
| Interest expense | 15.97M | 15.34M | 29.31M | 23.46M | 43.66M |
| Tax provision | 8.02M | -11.27000M | -901.42200M | -70.96300M | -65.49400M |
| Interest income | 18.03M | 10.48M | 16.61M | 22.75M | 22.83M |
| Net interest income | 2.06M | -4.85500M | -12.69900M | -0.71200M | -20.83300M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 8.02M | -11.27000M | -901.42200M | -70.96300M | -65.49400M |
| Total revenue | 2096.04M | 1846.28M | 1860.45M | 1704.05M | 1491.21M |
| Total operating expenses | 1570.81M | 1458.10M | 1432.44M | 1470.04M | 1349.47M |
| Cost of revenue | 483.67M | 470.51M | 524.27M | 359.47M | 315.26M |
| Total other income expense net | 92.03M | -15.33700M | 53.94M | 30.65M | 51.65M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Net income applicable to common shares | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 6841.60M | 6375.07M | 6003.32M | 5848.02M | 4690.04M |
| Intangible assets | 294.70M | 338.57M | 388.65M | 417.27M | 456.58M |
| Earning assets | - | - | - | - | - |
| Other current assets | 141.39M | 104.52M | 110.44M | 129.93M | 130.66M |
| Total liab | 1890.05M | 1771.92M | 1732.59M | 1742.02M | 1567.66M |
| Total stockholder equity | 4951.55M | 4603.16M | 4270.74M | 4106.00M | 3122.38M |
| Deferred long term liab | - | - | - | - | - |
| Other current liab | 354.24M | 346.56M | 329.40M | 289.21M | -13.03700M |
| Common stock | 0.19M | 0.19M | 0.18M | 0.18M | 0.18M |
| Capital stock | 0.19M | 0.19M | 0.18M | 0.18M | 0.18M |
| Retained earnings | -621.55400M | -789.19900M | -925.68900M | -861.60900M | -1720.70900M |
| Other liab | - | 73.50M | 113.69M | 174.32M | 98.12M |
| Good will | 196.20M | 196.20M | 196.20M | 196.20M | 197.04M |
| Other assets | - | 1604.19M | 1600.84M | 1574.39M | 612.00M |
| Cash | 755.13M | 724.53M | 587.28M | 649.16M | 437.45M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1177.02M | 588.88M | 539.82M | 492.55M | 932.50M |
| Current deferred revenue | 4.62M | 0.71M | 6.96M | 0.15M | 13.04M |
| Net debt | 378.75M | 358.49M | 491.80M | 425.99M | 410.67M |
| Short term debt | 502.66M | 10.38M | 10.46M | 11.75M | 361.88M |
| Short long term debt | 493.88M | - | - | - | 361.88M |
| Short long term debt total | 1133.88M | 1083.02M | 1079.08M | 1075.14M | 848.12M |
| Other stockholder equity | 5611.56M | 5396.04M | 5181.81M | 4983.57M | 4822.75M |
| Property plant equipment | - | 1114.32M | 1035.46M | 1032.47M | 1010.87M |
| Total current assets | 2956.09M | 2751.46M | 2274.39M | 2342.22M | 1942.14M |
| Long term investments | 611.13M | 333.83M | 507.79M | 285.47M | 411.98M |
| Net tangible assets | - | 4068.39M | 3685.89M | 3492.53M | 2468.76M |
| Short term investments | 318.68M | 567.01M | 426.60M | 416.23M | 316.36M |
| Net receivables | 633.70M | 461.32M | 373.40M | 448.35M | 377.40M |
| Long term debt | 593.10M | 1083.02M | 1079.08M | 1075.14M | 486.24M |
| Inventory | 1107.18M | 894.08M | 776.67M | 698.55M | 680.27M |
| Accounts payable | 315.51M | 231.24M | 193.00M | 191.43M | 570.62M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -38.64800M | -3.86700M | 14.43M | -16.13900M | 20.16M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | - | 0.18M | 0.18M | 0.18M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | - | -925.68900M | -861.60900M | -1720.70900M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 121.22M | 176.24M | 151.76M | 142.24M | 122.01M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 3885.51M | 3623.62M | 3728.94M | 3505.80M | 2747.90M |
| Capital lease obligations | 8.78M | 10.38M | 10.46M | 11.75M | 10.70M |
| Long term debt total | - | - | 1079.08M | 1075.14M | 486.24M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -20.02900M | -366.31300M | 26.17M | 108.19M | 358.98M |
| Change to liabilities | 59.02M | 12.35M | -93.89600M | 80.22M | 47.30M |
| Total cashflows from investing activities | -20.02900M | -366.31300M | -53.62100M | -31.02600M | 264.35M |
| Net borrowings | -2.60500M | -3.03900M | 210.76M | -5.08700M | -374.95300M |
| Total cash from financing activities | -18.65000M | -0.04800M | 181.12M | -74.67400M | -388.00700M |
| Change to operating activities | -5.10400M | 19.83M | -17.20600M | -32.77500M | -9.78800M |
| Net income | 141.56M | -64.08000M | 859.10M | -23.84800M | -77.21100M |
| Change in cash | 137.25M | -61.88200M | 211.71M | -56.53600M | -104.04600M |
| Begin period cash flow | 587.28M | 649.16M | 437.45M | 493.98M | 598.03M |
| End period cash flow | 724.53M | 587.28M | 649.16M | 437.45M | 493.98M |
| Total cash from operating activities | 175.90M | 304.54M | 85.36M | 48.26M | 20.21M |
| Issuance of capital stock | - | - | - | - | 0.00000M |
| Depreciation | 101.97M | 108.04M | 105.17M | 105.30M | 95.67M |
| Other cashflows from investing activities | 103.33M | -24.64100M | 34.52M | 5.81M | 49.99M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -68.26400M | -35.06000M | -61.15100M | -107.55400M | -23.74700M |
| Change to account receivables | -82.03300M | 65.57M | -59.03500M | -37.85200M | -54.27400M |
| Sale purchase of stock | 0.00000M | 49.19M | -50.00000M | 31.61M | 67.49M |
| Other cashflows from financing activities | -16.04500M | 2.99M | 613.03M | -69.58700M | -13.05400M |
| Change to netincome | 28.75M | 185.24M | -671.56800M | 56.66M | 19.62M |
| Capital expenditures | 131.54M | 119.22M | 137.52M | 163.41M | 144.62M |
| Change receivables | - | 65.57M | -59.03500M | -37.85200M | -54.27400M |
| Cash flows other operating | - | 23.17M | -10.33500M | -36.61700M | -18.70200M |
| Exchange rate changes | - | -0.05700M | -1.15000M | 0.90M | -0.59800M |
| Cash and cash equivalents changes | - | -61.88200M | 211.71M | -56.53600M | -104.04600M |
| Change in working capital | -96.38300M | 66.03M | -224.41700M | -101.09200M | -49.42000M |
| Stock based compensation | 196.31M | 197.26M | 189.71M | 159.87M | 148.82M |
| Other non cash items | -115.46600M | 12.89M | 44.71M | -9.20300M | -29.27300M |
| Free cash flow | 44.36M | 185.31M | -52.15400M | -115.14400M | -124.41200M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| BMRN Biomarin Pharmaceutical Inc |
0.55 0.89% | 62.52 | 71.57 | 34.36 | 7.23 | 3.54 | 7.25 | 56.60 |
| NVO Novo Nordisk A/S |
2.89 2.82% | 105.52 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
2.44 2.38% | 105.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.44 0.10% | 448.45 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-1.25 0.17% | 743.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.
770 Lindaro Street, San Rafael, CA, United States, 94901
| Name | Title | Year Born |
|---|---|---|
| Mr. Jean-Jacques Bienaime M.B.A., MBA | Chairman & CEO | 1953 |
| Mr. Brian R. Mueller | Exec. VP of Fin. & CFO | 1974 |
| Dr. C. Greg Guyer Ph.D. | CTO and Exec. VP of Global Manufacturing & Technical Operations | 1962 |
| Mr. Jeffrey Robert Ajer | Exec. VP & Chief Commercial Officer | 1962 |
| Dr. Henry J. Fuchs M.D., Ph.D. | Pres of Worldwide R&D | 1958 |
| Ms. Erin Burkhart | Group VP & Chief Accounting Officer | NA |
| Traci McCarty | VP of Investor Relations | NA |
| Mr. George Eric Davis | Exec. VP, Gen. Counsel & Sec. | 1971 |
| Mr. Philip Lo Scalzo | Sr. VP & Chief Compliance Officer | NA |
| Ms. Humaira Serajuddin | Sr. VP & Chief Marketing Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...